Meeting
2023 ASCO Annual Meeting
Prospective phase I study of checkpoint blockade for the treatment of patients with newly diagnosed high-grade glioma prior to radiochemotherapy: Results of nivolumab plus ipilimumab treatment arm.
Authors
Santosh Kesari
Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA
Santosh Kesari , Alexandre Wojcinski , Jaya M. Gill , Jose Arganda Carrillo , Naveed Wagle , Minhdan Nguyen , Judy Dang Truong , Tiffany M. Juarez
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT03425292
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2057)
DOI
10.1200/JCO.2023.41.16_suppl.2057
Abstract #
2057
Poster Bd #
414
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Multicenter phase I/II trial of encorafenib with and without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic BRAF-mutant melanoma.
First Author: Max Jameson-Lee
Poster
2023 ASCO Annual Meeting
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.
First Author: Zeynep Eroglu
Poster
2022 ASCO Annual Meeting
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).
First Author: Julia Katharina Schwarze
Poster
2021 ASCO Annual Meeting
A phase I trial of plinabulin in combination with nivolumab and ipilimumab in patients with relapsed small cell lung cancer (SCLC): Big Ten Cancer Research Consortium (BTCRC-LUN17-127) study.
First Author: Jyoti Malhotra